Subscribe to our Newsletters !!
Cell therapy is a medical breakthrough in addressi
Chromium, a transition metal with profound pharmac
Few names in the medical history have had a profou
We are pleased to announce that we have recently e
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of Mi
Randox Laboratories and Qnostics have today announced that they have entered into a strategic partnership.
The partnership will provide Randox Laboratories with access to the Qnostics molecular range of products for sales and distribution purposes, complementing the established Randox Laboratories portfolio.
Access to the Randox Laboratories commercial capabilities will enhance Qnostics’ market penetration, whilst also maintaining their presence as an independent provider of molecular quality controls and custom services.
MD of Randox Laboratories, Dr Peter FitzGerald said;
“We are delighted to have agreed a strategic partnership with Qnostics, an arrangement we see as mutually beneficial. We look forward to working together to strengthen the molecular service we provide to our global markets whilst enhancing the Qnostic brand and market penetration.”
Dr Frank Opdam, Head of Commercial of Qnostics said;
“We believe this is an ideal partnership. We look forward to working with Randox Laboratories and the growth that will result from the global access this partnership will provide to Qnostics for its expanding range of molecular quality control products.”
Contact Information
For further details please contact:
Qnostics
Email ID: [email protected]
Randox Laboratories Ltd